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1. Introduction 
Urinary tract infection (UTI) is one of the most common infections in humans. It is estimated 
that 40% of women and 12% of men will experience a symptomatic UTI, with incidences 
peaking in their early 20s or after age 85, respectively (1). Approximately 25% of these women 
will experience recurrence within 6 to 12 months (1).  Uropathogenic Escherichia coli (UPEC) is 
the most common etiological agent responsible for uncomplicated UTI. In the United States 
alone, the estimated annual societal cost of UTI is more than 3 billion dollars (1). 
Despite significant advances in the understanding of UPEC biology, mechanistic details 
regarding the host response to UTI and full comprehension of genetic loci that influence 
susceptibility require additional work. As new and intriguing details of how uropathogens 
initiate infections and persist within the urinary tract have emerged, so has important 
information regarding how the immune system functions within the urinary tract. The 
complex cross-linking for innate and adaptive immune response as well as humoral and 
cellular effectors is the key to the urinary tract immune system and to its defense against 
pathogenic microorganisms. As antibiotic therapy becomes increasingly ineffective, 
modulating the innate and adaptive immune system in the urinary tract using TLR4 ligands 
and other immunomodulators may become viable options to combat UTIs. 
2. Innate responses to urinary tract infections  
2.1 Host factors that prevent colonization of urinary tract with UPEC 
Uroepithelial adherence is critical for establishment of UTI. The urinary tract, comprised of 
the urethra, bladder, ureters and the kidneys, represents a formidable mechanical barrier to 
infection. In addition to the relative impregnability of the epithelium lining the tract, 
potential pathogens have to contend with the powerful flushing action of urine and the 
aggregating actions of urinary mucins (2;3). UPEC strains possess an impressive repertoire 
of adhesins that enable them to aggregate and adhere to cellular surfaces (4).  Consequently, 
the first line of host defense against UTI is concentrated on preventing UPEC adherence to 
the bladder mucosa. The luminal surface of the bladder is lined with highly sulfated and 
anionic glycosaminoglycans (GAGs) that contribute to bladder wall impermeability and 
afford an antimicrobial anti-adherence property. Intuitively, urine flow seems to be a 
convenient defense mechanism; however, FimH binds to mannose moieties using “catch-
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bonds,” interactions that are actually strengthened by the sheer stress induced during urine 
flow (5). Thus, more active mechanisms, like umbrella cell exfoliation (6) that occurs by an 
apoptosis-like mechanism and is promoted by FimH (7) remove adherent UPEC.  Tamm-
Horsfall protein (THP) is a high-molecular-weight protein present in human urine (8) that 
binds E. coli fimbriae (9) by virtue of its mannose moieties, inhibiting fimbrial interaction 
with uroplakin receptors (10). This phenotype translated in vivo as thp−/− mice were 
unable to control lower-UTI (11). THP also appears to act as an innate-adaptive 
immunoregulatory molecule that can activate dendritic cells (12). 
2.2 Host signaling in response to UPEC recognition  
Of the various immune surveillance molecules the Toll-like receptor (TLR) family is the best 
characterized (13-16). Unlike the receptor for the FimH adhesin of UPEC, which promotes 
bacterial invasion and subsequent invasion of BECs (17), the TLRs function by detecting 
different PAMPs and then mobilizing appropriate immune defences. The common TLRs 
encountered in the urinary tract include TLR2 (recognizes bacterial lipoteichoic acid or 
lipoprotein), TLR3 (recognizes double stranded RNA), TLR4 [recognizes 
lipopolysaccharides (LPS)], TLR5 (recognizes flagellin), TLR9 (recognizes unmethylated 
CpG DNA of bacteria and viruses), and TLR11 (recognizes profiling of parasites). TLR5 and 
TLR11 are other TLRs shown in in vivo studies to contribute to immune defence in the 
urinary tract (13;16). TLR5 is predominantly expressed on bladder cells whereas TLR11 is 
primarily on kidney cells  (13;16). Perhaps the best studied of these TLRs is TLR4, which is 
well expressed on epithelial cells of the kidney and bladder (14). 
Toll-like receptor 4 (TLR4) is important for signalling of innate immunity in response to 
UTI 
Upon successful adherence to the uroepithelium, Toll-like receptor (TLR) recognition of 
pathogen-associated molecular patterns generates signaling cascades to control infection 
and direct adaptive responses (18). Particular close attention has been given to the role of 
TLR4 in UTIs.  LR4 mutation (TLR4-/-) mice failed to initiate an immune response against 
UTI, and they developed an asymptomatic carrier state resembling human asymptomatic 
bacteriuria (ABU) (19) . Interestingly, recent studies have shown that TLR4 has antimicrobial 
roles that appear to be specific to the urinary tract (20) (21). These include promotion of IL-6 
and IL-8 secretion by activation of the MyD88- or cAMP-dependent signaling pathway, 
inhibition of bladder epithelial cell (BEC) invasion by bacteria, and expulsion of UPEC 
harboring in BECs (21-24). Clinical research found that children with UTI have lower TLR4 
expression than age-matched controls without UTI. In relation to UTI history, children with 
low TLR4 expression on their neutrophils display an asymptomatic bacteriuria (ABU) 
carrier state lacking both inflammation and bacterial clearance (25).   Meanwhile, adult 
patients with chronic UTI were found to have lower TLR4 expression than healthy controls 
without UTI (26). All these imply that enhanced TLR4 expression possibly contributes to 
increased mucosal immune response. 
It has been known that C3H/HeJ mice, harboring a mutation in the Toll/interleukin-1 
receptor (TIR) domain of TLR4, cannot resolve UTI as efficiently as LPS-responsive 
C3H/HeN counterparts (27). In accordance, tlr4−/− mice had significantly higher bacterial 
burdens in their bladders than similarly infected wild-type mice (28).  This clearance defect 
is the result of insufficient downstream cytokine and chemokine production and neutrophil 
recruitment (29).  Data from mouse chimeras disclosed that TLR4 on both stromal and 
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hematopoietic cells is critical for normal inflammatory responses and clearance of UPEC in 
the bladder and kidney (30). Correspondingly, children with low TLR4 expression on their 
neutrophils display an asymptomatic bacteriuria (ABU) carrier state lacking both 
inflammation and bacterial clearance (25). A similar response is exhibited by C3N/HeJ mice 
following UPEC inoculation (31). 
TLR4-mediated signaling is mainly LPS independent 
TLR4-mediated signaling in the urinary tract does not appear to be the result of the 
archetypal interaction with LPS. Both the role of LPS in and the molecular trigger of TLR4 
signaling by UPEC are topics of debate (32). Studies using the A498 human kidney cell line 
indicate that TLR4 signaling in response to UPEC requires P fimbriae and can be mediated 
independently of LPS (33). Mechanistic details regarding this phenomenon include P 
fimbriae binding to surface glycosphingolipids (GSLs) and subsequent release of the GSL 
membrane-anchoring domain, ceramide (34). Ceramide appears to act as a TLR4 agonist and 
the putative intermediate for TLR4 signaling initiated by P fimbriae (34). Lastly, the FimH 
tip adhesin of type 1 fimbriae was recently shown to directly interact with TLR4, an 
additional means for LPS-independent stimulation by UPEC fimbriae (35) 
TLR4-mediated signaling is also LPS dependent 
In contrast to LPS-independent signaling by P fimbriae, there appears to be a cooperative 
stimulation of TLR4 by LPS and type 1 fimbriae (36). This cooperative stimulation directly 
correlates with the level of cluster of differentiation 14 (CD14) expression on bladder cells 
(24). CD14 is an accessory molecule required for optimal TLR4 signaling in response to LPS 
(24). Immunohistochemical (IHC) analysis of human bladder biopsies revealed that CD14 
expression is localized to the submucosa (37), suggesting that uroepithelial cells exposed to 
the lumen have little to no CD14 expression and therefore may not respond efficiently to 
LPS alone. These results support a role for both independent and cooperative TLR4 
stimulation by UPEC fimbriae.  
Downstream signalling pathways important for signalling of innate immunity in 
response to UTI 
Infection of knockout mice has revealed critical roles for myeloid differentiation primary 
response protein 88 (MyD88), TIR domain-containing adaptor inducing beta interferon (TRIF), 
and TRIF-related adaptor molecule (TRAM) in signaling for UPEC clearance (38). It is also 
apparent that different fimbrial types influence the corresponding downstream signaling 
pathways (38). Regardless of the fimbria involved in stimulation, all pathways involving these 
adaptor molecules result in activation of NF-κB and proinflammatory gene expression. Song 
and colleagues identified an accompanying proinflammatory bladder cell signaling pathway 
that is also dependent on TLR4 but results in a spike in intracellular calcium levels (39). This 
calcium spike leads to adenylyl cyclase 3 (AC3)-mediated increase in cAMP, protein kinase A 
(PKA) activation, phosphorylation of the cAMP response element-binding protein 
transcription factor (CREB), and proinflammatory gene expression such as transcription of IL-
6 and IL-8 (39). Using selective blockade of these signaling cascades, Song et al. determined 
that activation of epithelial IL-6 secretion by E. coli might even be faster via the CREB pathway 
than the canonical pathway and can also be activated by TLR2 and TLR3 ligands (39). 
Other TLR pathways important for signalling of innate immunity in response to UTI 
Other TLR pathways have been implicated in host defense during UTI. In a recent case-
control study of adult women with a history of UTI in which TLR genes were examined, 
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polymorphisms in TLR1, TLR4, and TLR5 were correlated with protection from, or 
susceptibility to, some UTI phenotypes (40). TLR2 is stimulated by peptidoglycan, as might 
be presented by gram-positive uropathogens, including Enterococcus and Staphylococcus 
species, as well as by lipoproteins and perhaps OmpA (41) of other extraintestinal 
pathogenic E. coli.  Tlr2−/− mice appear to respond normally to acute UTI (31). TLR5 
appears to play a UPEC recognition role in the bladder (13). TLR5 recognizes the structural 
subunit of flagella, which are essential for UPEC motility in the urinary tract induces 
inflammatory cytokines and chemokines (13). Mice lacking TLR5, which responds to 
bacterial flagellin, permit higher bacterial loads in the bladder and kidney following 
transurethral inoculation (13). In contrast to TLR5 which has a bladder-specific role during 
UTI, TLR11 has a kidney-specific role during UTI (16). The murine receptor TLR11, 
associated with a pseudogene in humans, also appears to respond to uropathogenic bacteria 
(16). Conversely, tlr11−/− mice are more susceptible than wild-type mice to UPEC kidney 
infection (16) a UPEC-encoded homolog has yet to be identified for TLR11 ligand. The fact 
that there is a stop codon in the open reading frame of human genomic and cell line tlr11 
sequences may help explain acute and recurrent UTI susceptibility in humans (16).  
Other Non-TLR pathways important for signalling of innate immunity in response to 
UTI 
Surface molecules other than TLRs are also involved in host-UPEC interactions. Upon UPEC 
exposure, the cytoplasmic tail of uroplakin IIIa undergoes phosphorylation, and 
intracellular calcium levels increase, presumably important events for uroepithelial cell 
apoptosis and exfoliation(42) Although uroplakin Ia is thought to be the main receptor for 
UPEC FimH in vivo (167, 256, 286), type 1 fimbriae may bind to a number of host molecules, 
including uroplakin complexes (42) extracellular matrix proteins (43) CD molecules (44), 
and integrins (45). The CD44 ligand, hyaluronic acid (HA), accumulates in the urinary tract 
during UTI; UPEC can bind HA, thereby facilitating interaction with CD44 and tissue 
invasion (46). In accordance with this, cd44−/− mice are more resistant to UPEC kidney 
colonization and successive dissemination (46). Also, there are still unidentified players in 
inflammation and clearance of UPEC. For example, LPS-responder C3H/OuJ mice were 
found to be equally susceptible to UTI as non-LPS-responder C3H/HeJ mice yet 
demonstrated elevated levels of inflammation (47), revealing a susceptibility locus to map. 
2.3 Metabolic host pathways against UPEC during UTI 
Host factors against iron metabolism of UPEC 
That E. coli strains causing UTI have several functionally redundant systems dedicated to 
iron uptake (48) suggests that the urinary tract, like other host niches, is an iron-limited 
environment (49). Siderophores are secreted iron-chelating molecules that allow bacteria to 
scavenge free and host protein-bound iron (50). Enterobactin, for instance, can bind free 
ferric ions with a higher affinity than transferrin (51)  a host iron transport protein 
responsible for regulating the free iron concentration in serum(52). A transferrin family 
member, lactoferrin, evokes antimicrobial activity by sequestering iron over a range of pH. 
Lactoferrin is secreted by kidney cells and is found in neutrophil granules and thus could be 
involved in combating UTI (53). Both transferrin and lactoferrin have been shown to evoke 
direct antimicrobial activity by disrupting Gram-negative membranes (54). 
In addition to iron sequestration, there are host factors that directly counter the action of 
siderophores. Early studies indicated that serum albumin, alone or in concert with other 
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serum proteins, can impede bacterial siderophore function (55). In addition, the mammalian 
protein lipocalin 2 (Lcn2) can bind and sequester enterobactin and similar catecholate 
siderophores (56). Lcn2 inhibits enterobactin-dependent propagation of E. coli in vitro, and 
lcn2−/− mice are unable to control systemic E. coli burdens as well as wild-type mice (56) 
Production of Lcn2 is induced by TLR4, implicating iron regulation as a part of the immune 
response to infection(56). Murine GeneChip and quantitative PCR (qPCR) analyses 
confirmed that Lcn2 mRNA is upregulated by the uroepithelium of infected mice (57). 
Interestingly, these results were obtained in C3H/HeJ mice, indicating that a TLR4-
independent signaling pathway can activate transcription of the lcn2 gene in response to 
UTI. Not surprisingly, UPEC has evolved a mechanism to counter Lcn2 siderophore 
sequestration. Encoded within the iroA gene cluster are glycosyltransferases that modify 
enterobactin in such a way that it cannot be bound by Lcn2 (58). Thus, both the host and 
UPEC have systems in place to manage their own iron stores and to inhibit iron acquisition 
by the other—a molecular arms race for an essential nutrient. 
2.4 Metabolic host factors against UPEC 
The role for bacterial central metabolism during infection has only been recently appreciated 
(59).  Genes important for glucose import were upregulated by the uroepithelium of 
C3H/HeJ mice experiencing UTI, possibly for either nutrient sequestration or energy to 
combat infection(57).  This fact, coupled with the knowledge that UPEC does not chemotax 
toward glucose in vitro (60) or utilize glucose as a primary carbon source in vivo (61) 
implies that UPEC may have evolved to use alternative carbon sources in the urinary tract. 
These results imply that nutrient acquisition is also a crucial aspect of bacterial pathogenesis 
and the host response that may influence the outcome of UTI. 
2.5 Epithelial host pathways against UPEC during UTI 
Life cycle of UPEC in urinary tract epithelium 
There has been a growing body of literature revealing that UPEC appears to have three 
distinct intracellular lifestyle components within the urinary tract (62). The first is uptake by 
apical endocytosis of Rab27b+/CD63+ fusiform vesicles, which are subsequently recycled 
back to the cell surface and exocytosed (20). The other two pathways both begin with uptake 
into a membrane-bound compartment which can lead to either a quiescent nonreplicative 
existence (63) or escape from compartmental life to undergo a highly replicative phase in the 
cell cytoplasm. While internalization via the fusiform vesicle pathway may be a side effect of 
normal bladder epithelium function, cellular uptake by the other two pathways is perhaps 
intended by UPEC to establish a reservoir to persist in the urinary tract (63). Indeed, UPEC 
has been shown to exist in the urinary tract for weeks, even after antibiotic treatment (64). 
Infection of 10 genetically distinct mouse strains also revealed that some strains were more 
susceptible to persistence than others, indicating that host hereditary components may also 
contribute to the ability of UPEC to persevere in the urinary tract (65). 
2.6 Epithelial host factors have important role against compartmental escape of UPEC 
Infected mouse bladder explants monitored by time lapse fluorescence videomicroscopy 
generated a model for the intracellular UPEC life cycle instigated after uptake in a 
membrane-bound compartment (nonfusiform vesicle route)(66). While the mechanism of 
compartmental escape remains undefined, once contained in cytoplasmic “intracellular 
bacterial communities” (IBCs), UPEC can undergo several changes in morphology, 
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categorized as early, middle, and late IBC stages (66). Late IBCs that escape exfoliation with 
umbrella cells contain filamentous UPEC that are not present in C3H/HeJ mice, indicating 
that this morphological change may be a bacterial stress response to TLR4-mediated 
immune activation (66). This murine background also experienced increased incidence and 
severity of IBCs compared to immunocompetent mice (66). Urothelial cells proximal to IBCs 
in C3H/HeJ mice upregulate transferrin receptor, Lcn2, complement system components 
(C3, factor B, and CD55), and lysozyme (57). Involucrin and suprabasin transcripts were also 
increased, indicating that, in addition to gene products that function to eradicate bacteria, 
proteins important for epithelial integrity may be an imperative host response during UTI 
(57). 
Notably, TLR4 also plays a noninflammatory role in host defense against UPEC by 
modulating the activity of the observed secretory and vesicular internalization pathways. 
TLR4-mediated PKA activation suppresses the lipid raft endocytic pathway (21), a possible 
effort to prevent the establishment of persistence reservoirs. Also along these lines, UPEC 
exocytosis in fusiform vesicles was actually accelerated by TLR4-mediated recognition of 
LPS and dependent on the activities of cAMP, Rab27b, caveolin-1, and the scaffolding 
protein MyRIP (22). 
The role of urothelial regeneration in response to UPEC infection 
One of the consequences of UPEC infection is exfoliation of the superficial facet cell layer 
that lines the surface of the bladder lumen (67).  Microarray analyses probing regenerative 
signals revealed that, in addition to genes involved in cell biological processes, 
inflammatory cytokines, chemokines, signaling molecules, and transcription factors are also 
upregulated in response to inoculation (68). While regeneration itself appears to be a 
function of basal stem/progenitor cells in the transitional epithelium (68) studies of the gut 
epithelium unveiled macrophages as “cellular transceivers” that relay MyD88-dependent 
inputs from the epithelium to colonic epithelial progenitors via direct contact (69). Whether 
or not macrophages play a similar role in the urinary tract remains unknown. 
2.7 Antimicrobial peptides, cytokines and chemokines against UPEC during UTI 
Antimicrobial peptides (AMPs) are short positively charged peptides secreted by both 
epithelial and hematopoietic cells that disrupt bacterial membranes and can be chemotactic 
for certain immune cells (70). Human ǃ-defensin-1 mRNA and protein were found in kidney 
tissue, implicating this AMP in host defense against UPEC (71). More convincingly, mice 
deficient in defb1, a murine homolog of human ǃ-defensin, have a significantly higher 
incidence of bacteriuria (72). Murine ǃ-defensin is also a dendritic cell (DC) ligand that 
instigates upregulation of costimulatory molecules and maturation (73). The human 
cathelicidin, LL-37, and its murine homolog, cathelin-related antimicrobial peptide 
(CRAMP), are secreted in response to UPEC exposure (44). Studies using CRAMP-deficient 
mice revealed that epithelial-derived CRAMP is important during the early stages of UTI 
while leukocyte-derived CRAMP likely functions later when bacteria penetrate the kidney 
epithelium (46). 
2.8 Cytokines and chemokines against UPEC during UTI 
The role of IL-8-mediated neutrophil recruitment in phenotypic susceptibility to UTIs  
Human C-X-C ligand 8 (hCXCL8; interleukin-8 [IL-8]) is the main chemoattractant for 
neutrophils in humans, and murine CXCL1 (mCXCL1) and mCXCL2 (also known as KC 
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and MIP-2, respectively) are the functional mouse homologs of IL-8 (26).  Bladder and 
kidney cell lines secrete IL-8 in response to UPEC (26). Human and murine studies both 
demonstrate that neutrophil migration to the UPEC-infected urinary tract is dependent on 
IL-8 (26). Additionally, mCXCL2 secretion is dependent on TLR4, as secretion was deficient 
in infected C3H/HeJ mice (100). hCXCR1 and hCXCR2 are receptors for a number of 
chemokines, including IL-8 (26). Both are expressed in bladder and kidney biopsies, and 
transmigration studies indicated that hCXCR1 plays a dominant role in IL-8-dependent 
neutrophil migration (74). Consistent with this, children prone to pyelonephritis tend to 
have low hCXCR1 expression and heterozygous hCXCR1 polymorphisms (74). Using a large 
cohort of families that included children with a history of recurrent UTIs, Svanborg and 
colleagues found that low CXCR1 (IL-8 receptor) expression levels correlated with the 
incidence of acute pyelonephritis (75). Subsequently, CXCR1 mutations and polymorphisms 
were identified in several patients with recurrent pyelonephritis (76). Although CXCR1 
mutations were not correlated with pyelonephritis in a separate cohort of Italian children, 
IL-8 gene polymorphisms were found in this latter group (77). hCXCR1 deficiency results in 
impaired bacterial clearance but, unlike TLR4 deficiency, with intact inflammatory signaling 
that ultimately results in tissue damage(31).  
Similarly, mice lacking mCXCR2 (the functional homolog for hCXCL1) experience 
subepithelial accumulation of neutrophils, increased bacterial titers, and renal scarring after 
UPEC inoculation (78) and increased susceptibility to experimental UTI and urinary tract–
derived bacteremia (79;80). These data indicate that normal function of neutrophils, their 
chemotactic ligands, and their chemokine receptors are required for bacterial clearance 
without postinflammatory sequelae. 
The role of other cytokines in phenotypic susceptibility to UTIs  
Despite ample information on IL-8 in vitro and in vivo, a complete picture of the cytokine 
and chemokine dynamics during UTI was lacking. In response, a longitudinal assessment 
using a Bio-Plex format was conducted(81). Chemokine (C-C motif) ligand 2 (CCL2 or MCP-
1), CCL4 (or MIP-1b), CCL5 (or RANTES), CXCL1, IL-1ǃ, IL-6, IL-12p40, IL-17, tumor 
necrosis factor alpha (TNF-ǂ), and granulocyte-colony stimulating factor (G-CSF) were all 
upregulated in bladder homogenates from UPEC-infected C57BL/6 mice (81). These results 
agreed with patient and cell line data regarding upregulation of IL-6 in response to UPEC 
(82). In mice, TNF-ǂ expression was elevated at 1 h post-inoculation for rapid mobilization 
of acute responses (81); this waned at later time points, likely to prevent the deleterious 
effects of uncontrolled TNF-ǂ signaling (16). Expression of most cytokines and chemokines 
peaked around 24 h post-inoculation, returning to near baseline at 2 weeks (81). These 
dynamics correlate well with the peak and resolution of bacterial burdens in C57BL/6 
mice(81). One notable exception was IL-17, which was highly upregulated from 6 h to 1 
week post-inoculation, remaining above baseline through the 2-week experimental 
duration(81).  Importantly, IL-17A (the Th17 signature cytokine) contributes to innate 
clearance of UPEC through a mechanism involving cytokine and chemokine secretion and 
macrophage and neutrophil influx (26). Similar to TLR adaptor molecule usage (38) the type 
of fimbriae expressed also seems to influence the repertoire of chemokines secreted. 
Specifically, kidney cells exposed to type 1-fimbriated UPEC secrete neutrophil-associated 
chemokines, while P fimbriae-stimulated cells secrete chemokines targeting antigen-
presenting cell (APC)- and Th1-specific cytokines, exemplified by CCL2 and CCL5 
expression (83). In addition, IFN-Ǆ and IL-4 (signature cytokines of the Th1 and Th2 
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lineages, respectively) and IL-10 (a T-regulatory [Treg] effector cytokine) knockout mice 
were tested for susceptibility to both acute cystitis and pyelonephritis (84). While il4−/− and 
il10−/− mice appear to experience infection dynamics similar to the wild type, ifnǄ−/− mice 
had increased incidence and severity of UTI (84) implying a role for IFN-Ǆ and Th1-
mediated inflammatory responses during UTI. 
2.9 The role of neutrophils in immune responses to UPEC-mediated UTI 
Infected mouse bladders examined histologically display thickening of epithelium 
accompanied by robust infiltration of inflammatory cells and edema in the lamina propria 
(85). Neutrophils are the most rapid and abundant responders to the infected urinary tract 
(85). Efficient migration of neutrophils requires intracellular adhesion molecule 1 (ICAM-1) 
expression by epithelial cells and ǃ2 integrin (CD11b/CD18) expression by neutrophils (30). 
G-CSF is also required for the neutrophil response, and unexpectedly, mice with neutralized 
G-CSF are more resistant to UTI(81). Although monocyte/macrophage numbers were 
similar in anti-G-CSF-treated mice, cytokines important for macrophage activation were 
upregulated, potentially leading to accelerated clearance by enhanced phagocytic killing 
(81). Despite counterintuitive phenotypes with respect to cytokine knock-down, antibody-
mediated knockdown of the neutrophil population confirmed their crucial role in bacterial 
clearance, especially within the kidney (86). Lastly, the electrostatic properties of the UPEC 
P fimbrial tip adhesin may interfere with neutrophil binding, a potential host response 
evasion tactic specific to the kidney (86). 
2.10 The role of APCs in immune responses to UPEC-mediated UTI 
Compared to the neutrophil response, relatively little is known about APCs in the context of 
UTI. In mice, resident CD11c+ cells that express low to intermediate levels of F4/80 and 
CD11b macrophage markers were found in the kidney (87) while CD11c+ cells expressing 
the major histocompatibility class II activation marker were found in the bladder (30). In 
spite of macrophage marker expression, CD11c+ kidney cells had physical and functional 
characteristics of DCs (87). At 24 h post inoculation, CD11c+ cells that migrate to the bladder 
did not express CD8ǂ, Gr-1, or B220 and thus were not plasmacytoid or lymphoid but 
appeared to be TNF-ǂ- and inducible NOS (iNOS)-producing (Tip)-DCs (88) that express 
intermediate levels of CD11b. Infection studies in mice lacking Tip-DCs suggested that they 
are not necessary for the host response to acute UTI (88). Since Tip-DCs are necessary for the 
generation of mucosal IgA (89), their role may lie in mediating the humoral response to 
UPEC. Similar to what was observed for DCs, there appears to be a resident population of 
macrophages in bladder tissue that increases by several orders of magnitude in response to 
UTI (81). Monocytes expressing high levels of Gr-1, which can give rise to macrophages or 
DCs, are also recruited to the bladder in response to UPEC infection. Release of these cells 
from the bone marrow was dependent on CCR2 (90), and, correspondingly, CCL2 is 
upregulated in the bladder response to UTI(81). 
2.11 The role of the antimicrobial compound nitric oxide (NO) in immune responses to 
UPEC-mediated UTI 
Some of the factors utilized by neutrophils, macrophages, and DCs for pathogen uptake and 
destruction have been described during UTI. iNOS generates the antimicrobial compound 
nitric oxide (NO) from l-arginine and was originally reported to be secreted by macrophages 
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(91). Although iNOS is rapidly upregulated in the inoculated bladder(92) two independent 
groups reported that inos−/− mice are equally as susceptible to UTI as wild-type mice, 
suggesting that neuronal NOS, endothelial NOS, or myeloperoxidase may act as 
compensatory factors (93) Alternatively or in addition, inos−/− animals may lack a 
colonization phenotype because there are several factors (Hfq and Nsr-regulated genes, 
polyamines, and flavohemoglobin) expressed by UPEC that enhance tolerance to reactive 
nitrogen species in vitro (94) suggesting that NO production may be an ineffective host 
defense against UPEC.  
2.12 The role of the complement in immune responses to UPEC-mediated UTI 
With respect to the complement system, it appears that UPEC is able to bind C3 to enter host 
uroepithelial cells via the surface receptors Crry or CD46 (95). Correspondingly, c3−/− mice 
are more resistant to renal damage and infection (95). As C3 levels are significantly higher in 
the urine of UTI patients (96) UPEC may stimulate C3 production for pathogenic means or 
has evolved to exploit this host defense factor. 
2.13 The role of innate-like lymphocytes (ILLs) in acute UTI host defense  
Infection studies using severe combined immunodeficient (SCID) mice that lack functional B 
and T cells and nude mice that lack thymically derived T cells provide preliminary evidence 
of a role for innate-like lymphocytes (ILLs) in acute UTI host defense (97).  Epithelial Ǆǅ T 
cells, B-1 cells, and natural killer T (NKT) cells are ILLs: cellular subsets that have relatively 
invariant receptors and reside in specific locations of the body (26). After a 2-day primary 
infection, SCID mice had significantly higher bacterial counts in their bladder and kidneys, 
while nude mice were colonized similarly to wild-type animals (97). The lack of a 
colonization phenotype in nude mice suggests that either antibody responses independent 
of thymus-derived T-cell help or extrathymically produced T cells may play a role in innate 
clearance of UPEC. The latter suggestion has some experimental support.  
The role of ┛├ T cells 
Ǆǅ T cells can be produced extrathymically and rapidly secrete cytokines in response to 
stimulation (98). Resident Ǆǅ T cells found in the bladder increase in response to UTI (26), 
and TCR ǅ−/− mice are more susceptible to UTI than isogenic controls (84). As Ǆǅ TCR+ 
cells express IL-17A during UPEC-mediated UTI  (26) this rapid-response cell population 
may function in concert with other innate factors to mediate neutrophil influx for clearance 
of UPEC.  
The role of B-1 cells 
B-1 cells spontaneously secrete large quantities of polyspecific IgM against bacterial and 
self-antigens, and in contrast to conventional (B-2) B cells, do not require T-cell help (99). 
While IgM secreted by B-1 cells might play a role in innate clearance of UPEC, current 
evidence suggests otherwise. JHD mice, lacking both B-1 and B-2 cells (100) infected and 
monitored over a 14-day time period exhibited no significant increase in incidence or 
severity of cystitis (84).  
The role of NK T cells 
On a final note regarding ILLs, administration of ǂ-galactosylceramide (ǂ-GalCer), a ligand 
for CD1d-restricted NKT cells, alleviates renal UPEC infection (101).  Consistent with this, a 
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resident population of NK1.1+ cells (potentially NK or NKT cells) in the bladder of C57BL/6 
mice that increases in response to UTI has been reported (26). Studies using a systemic E. 
coli infection model suggested that, similar to Ǆǅ T cells, NKT cells may act as early 
amplifiers of the innate immune response to UTI by rapid cytokine secretion (102). 
3. Genetic factors that contribute to innate immunity 
Although susceptibility to UTI thus far appears to be related primarily to function of the 
innate immune system, additional determinants are likely important in this polygenic 
phenotype. For example, the increased susceptibility of C3H/HeJ mice was recently 
suggested to be due to at least two other loci in addition to Tlr4 (103) Accelerating progress 
in genomic sequencing methodology might facilitate the elucidation of other contributing 
genes, but these efforts may be hampered somewhat by the continuous, rather than discrete, 
nature of UTI susceptibility phenotypes in human populations. 
The individual's response to UTI is variable and the susceptibility to the infection is 
inheritable. Lundstedt et al. found in a family study, 15% of the relatives of pyelonephritis-
prone children had UTI history, whereas the value was 3% in the controls(75). A evaluation 
of a familal predisposition about women with recurrent UTI described that 65.5% of 
mothers, 60.7% of daughters, and 48.6% of sisters of the women had a similar history (104). 
Many studies discovered that genitic variations of TLR4 and CXCR1 are association with 
susceptibility to different type of UTIs. And TLR4(896)AG genotype and TLR4(896)G alleles 
could increase the risk for UTI in childhood (76;105), CXCR1 G (2608) C gene polymorphism 
and expression are strong linked to acute pyelonephritis in children (77). Reduced 
expression levels of CXCR1 and TLR4 in neutrophils are associated with pyelonephritis, 
recurrent cystitis, and asymptomatic bacteriuria in children and premenopausal women  
(25)(78;106). Although these studies suggest the association of gene polymorphisms and 
expression of TLR4 and CXCR1 to UTIs, whether the variants are associated with UTI in 
adults is still unknown. 
3.1 Other host factors that contribute to innate immunity 
Other mediators also shape the extent of the polymorphonuclear leukocyte (PMN) response 
to infection. Perpetuation of the PMN response might be controlled by cytokines such as IL-
17, which has an emerging role in bridging innate to adaptive immunity(107) and is present 
at high levels in the bladder at later time points. Plasminogen activator inhibitor type 1 
(PAI-1) influences cell migration through its effects on integrin binding; upon UPEC 
infection of mice lacking PAI-1, kidneys bore significantly higher bacterial burdens and 
fewer PMN infiltrates than wild-type counterparts did (108). UPEC infection was recently 
demonstrated to induce the secretion of granulocyte colony-stimulating factor (gCSF) in the 
bladder, and antibody-mediated depletion of this cytokine reduced PMN influx following 
UPEC infection (81).  
Finally, the secretion of a number of soluble antibacterial compounds into the urinary tract 
is induced by UPEC infection. UPEC infection also elicits the production of nitric oxide in 
association with upregulation of the iNOS gene (92). However, UPEC may employ 
strategies to resist the antibacterial effect of nitric oxide, as mice deficient in iNOS generally 
have shown no increased susceptibility to UTI (93;109). Among short antibacterial peptides, 
the human cathelicidin LL-37 is detectable in the urine during human cystitis, and mice 
deficient in its ortholog (CRAMP) demonstrate increased susceptibility to UTI (110).  
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4. Cellular and humoral adaptive immune responses to UPEC-mediated UTI 
Existing data regarding adaptive immune responses to UPEC are relatively limited. In a 
seminal study, Thumbikat and colleagues engineered a strain of UPEC to express 
ovalbumin to examine mechanisms behind antigen-specific adaptive immune responses in 
experimental UTI (111). In response to reinfection, CD4+ and CD8+ cells infiltrated the 
bladder and expressed the CD69 activation marker in the spleen (111), extending the 
findings of early IHC studies probing T- and B-cell populations in infected bladders (109). 
Furthermore, splenocytes, enriched splenic T cells, or serum antibodies from previously 
infected donor mice each protected wild-type naïve recipient mice against UPEC challenge 
(111). This result suggests that protection derived from natural infection is antibody 
mediated, as UPEC-specific antibody-secreting plasma cells could be present in both 
splenocyte and enriched T-cell preparations. As expected, transfers from naïve donor mice 
did not facilitate enhanced protection to recipients (111). This result is in contrast to a 
previous murine adoptive transfer study where SCID recipients receiving splenocytes from 
either naïve or vaccinated wild-type donors exhibited equal levels of enhanced clearance, 
despite the presence of antigen-specific plasma cells in the vaccinated donor cells (97). This 
result suggests that simply reconstituting immunosuppressed mice with lymphoid cells 
provides the means (likely stimulatory cytokines for phagocytic cells) for enhanced 
clearance. Conversely, wild-type recipient mice used in the former study only exhibited 
enhanced clearance when given cells or serum from antigen-educated, vaccinated donors 
(111), indicating that enhanced protection in individuals with intact immune systems will be 
provided only by stimulation of an effective adaptive immune response. 
4.1 The role of T cells in adaptive immune responses to UPEC-mediated UTI 
T-cell subsets are characterized by transcription factors and cytokines involved in their 
differentiation and the particular effector cytokines they secrete. To date, studies have not 
implicated a skew toward Th1- or Th2-mediated UTI immunity (111). DC phagocytosis of 
infected apoptotic cells is the key event required for DCs to secrete the cytokine milieu 
necessary for Th17 development (112), and both DCs and infected apoptotic cells are present 
in the bladder during UTI. Despite this connection, IL-17A is dispensable for the generation 
of a protective response in a murine reinfection model, suggesting that Th17 cells may not 
play a role in adaptive responses to UPEC infection (26). Similar to APCs and other 
lymphocytes, there are resident CD8+ cells in the bladder that increase in response to 
infection (26;111). It has been suggested that the observed CD8+ cells are either classical 
cytotoxic T cells or intraepithelial lymphocytes that exert cytotoxic effects on UPEC- or 
virus-infected cells or rapidly secrete cytokines to mobilize innate immune responses (26). 
Lastly, the role of Treg subsets in UTI host defense has not been formally examined. 
4.2 The role of antibody-mediated clearance in adaptive immune responses to UPEC-
mediated UTI 
Despite the lack of detail regarding T-cell responses to UTI, there is ample evidence for 
antibody-mediated clearance of UPEC. The genitourinary tract has been recognized as part 
of the secretory immune system (113). UPEC-specific antibodies are detected in the urine of 
infected patients and in the urine or serum of animals exposed to UPEC antigens (111). 
Urinary IgG and IgA from UTI patients are capable of inhibiting UPEC adherence (114).  
Patient studies have also suggested that antibody responses to pyelonephritis are, in 
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general, stronger and last longer than humoral responses to cystitis (115). Analysis of 
murine urine and serum samples collected before and after vaccination with OMP iron 
receptors allowed identification of immunological correlates of vaccine-induced protection 
against UTI (116). Specifically, levels of either urinary IgA or serum IgG (relative to serum 
IgM; denoted the class switch index) inversely correlated with bladder colonization in 
vaccinated mice (116).  Presumably, urinary IgA plays a direct role in UPEC clearance from 
the bladder mucosa, while IgG may be a marker for class switching by B cells or also play a 
direct role in mucosal bacterial clearance. As mentioned earlier, infected JHD mice had wild-
type levels of colonization in response to primary infection, suggesting that B cells have no 
role in innate clearance of UPEC (84). However, this result is not unexpected since both 
antigen presentation and antibody-mediated protection provided by B cells would likely 
play a role in adaptive responses, indicating a need for reevaluation of these mice in UPEC 
reinfection and vaccination challenge models. 
5. Immunomodulation as therapeutic option for UTI 
There are several practiced and proposed therapeutics for UTI management. Prophylactic 
treatments include estrogen in postmenopausal women  (117) or cranberry juice  (118) 
although the efficacy of the former remains controversial. Immunomodation strategies are 
emerging therapies for UTIs especially in the setting of increasing antimicrobial resistance. 
5.1 Non-vaccine strategies 
Since the lining of the urinary tract is highly enriched in TLR4 molecules, administering 
TLR4 specific ligands directly to the urinary tract could trigger TLR4 mediated innate 
immune responses thereby enhancing local reactivity and resistance to infection. Treatment 
of UPEC-infected mice with forskolin, a drug that increases intracellular cyclic AMP (cAMP) 
levels, expels UPEC from intracellular vesicles into the extracellular milieu, rendering the 
bacteria susceptible to immune responses and antibiotics (20). Similarly, exposing the 
bladder to protamine sulfate, a highly cationic protein, removes bound and intracellular 
UPEC by causing umbrella cells to exfoliate (63)), unfortunately with a significant level of 
discomfort, as reported by study volunteers (119). In addition to a number of nonspecific 
chemical treatments (120)), both small-molecule inhibitors (121) and specific antibody 
directed against FimH (122) demonstrated some utility in preventing bacterial adherence. 
While antibiotic therapy remains the standard treatment for UTI, overuse leads to 
deleterious alterations of the normal host microbiota (123) and selection for resistant strains 
(124), prompting the need for vaccine-mediated prevention of UTI. 
Astragalus is a Chinese herbal medicine, and Astragalus polysaccharide (APS) is its main 
components. Previous studies have demonstrated that APS could induce enhancement of 
expression of TLR4 on bladder epithelial cells (125) and astragalus also increases the TLR4 
expression on monocytes in UTI patients. These suggest that similar to LPS, APS can 
activate pre-inflammatory factor secretion during the early stages of infection similar to LPS, 
promote TLR4 expression, and involve mucosal innate immunity of the urinary tract. 
However it remains to be seen whether this herbal medicine can be a therapeutic option for 
UTI. 
These observations suggest that activators of the TLR4 signalling pathway in the urinary 
tract can be effective therapeutic agents against infections. Furthermore, it is not necessary 
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to use TLR4 ligands for activation of the pathway. Inducers of downstream substrates of the 
pathway are also effective activators of the innate immune response. Even if TLR4 ligands 
are employed for therapeutic use, it is unlikely that LPS will be the ligand of choice since 
LPS has intrinsic toxicity. A TLR4 ligand with greatly improved safety profiles, such as 
monophosphoryl lipid (MPL), could be used in its place (126). 
5.2 Vaccines 
The involvement of TLRs in the immune response to UTI and current knowledge of their 
ability to incite innate and direct adaptive responses make them attractive adjuvant 
candidates for UTI vaccines (127). These and other mucosal adjuvants and variations in 
vaccination routes and schedules must be tested in an effort to generate UPEC-specific local 
and systemic antibodies(128) and optimize production of immunological memory, not 
tolerance . A more detailed knowledge of adaptive immune responses to UPEC is a 
prerequisite for the development of next-generation candidate vaccines for the prevention of 
UTI. More recently, a variety of experimental approaches have been applied to search for 
immunodominant epitopes, revealing an array of new candidate targets, and thus a number 
of vaccine antigens have been explored (26). 
Lipopolysaccharide (LPS) and side chain (O) antigen as vaccine targets 
Early vaccine studies focused on the lipopolysaccharide (LPS) side chain (O) antigen (129). 
There are trends regarding the frequencies of particular O antigens among UTI isolates(130) 
and O-antigen-specific antibodies demonstrate an anti-adhesive effect (130).  Nonetheless, 
significant structural heterogeneity may represent an insurmountable obstacle for 
development of an O-antigen-based vaccine. Furthermore, a study evaluating antibody 
responses in mice intranasally vaccinated with a killed E. coli lacking capsule and O antigen 
demonstrated that these surface features actually obstruct optimal humoral responses (131) 
P fimbriae as vaccine targets 
Later studies involved vaccines directed against particular virulence factors. The pore-
forming toxin alpha-hemolysin (HlyA) and P fimbriae are proposed minimal factors 
required for colonization of and dissemination from the kidney (132). P fimbriae are 
adherence organelles that play a role in kidney colonization in mice and humans (133). 
There are convincing data using both murine (132) and primate models (134) that 
vaccination against P fimbriae or HlyA prevents renal colonization and damage. 
Additionally, to overcome P fimbrial allelic variability, linear peptide sequences that 
generated cross-reactive antibodies were evaluated as protective antigens (135). Despite 
these successes, vaccines targeting P fimbriae may not be effective because of their limited 
role during bladder colonization. Type 1 fimbria is a bona fide virulence factor of UPEC and, 
in contrast to P fimbria, is critical for bladder colonization (136). Animals vaccinated with 
various components of type 1 fimbriae had increased levels of antigen-specific antibodies 
and decreased levels of colonization upon challenge (137). Unfortunately, expression of type 
1 fimbria is subject to phase variation, allowing UPEC to evade humoral responses targeting 
this organelle(138). Additionally, since nonpathogenic isolates also express type 1 fimbriae 
(139), targeting this population may result in detrimental disruption of the host microbiota. 
Also of note, both P and type 1 fimbriae were not necessary for colonization of the human 
neurogenic bladder, indicating the need for alternative targets in certain high-risk patient 
groups (140). Although vaccines based on P or type 1 pilus components have generated 
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substantial mucosal antibody responses, protection from subsequent infections has been 
incomplete, perhaps because of phase variation in the expression of these antigens during 
infection. 
Iron pathway as target for vaccine 
Iron is essential for nearly all organisms (141) and UPEC strains encode a battery of genes 
involved in iron acquisition. Vaccination with UPEC outer membrane protein (OMP) 
fractions enriched for iron receptors protects against experimental sepsis (142). Additionally, 
mice vaccinated subcutaneously with denatured IroN, an OMP siderophore receptor and 
urovirulence factor (143), had both increased levels of antigen-specific serum IgG and 
reduced kidney colonization upon challenge (144). Undetectable levels of IgA in the bladder 
mucosa after this vaccination may explain why these animals were not protected from 
cystitis (144). Recently, a broad functional vaccinology initiative was conducted using an 
“omics” approach to identify vaccine candidates: UPEC proteins that are pathogen-specific, 
antigenic, surface-exposed, and in vivo expressed (26). Strikingly, the top targets identified 
by this approach were all OMPs functioning in iron uptake. Intranasal vaccination with 
three of six candidates afforded protection from cystitis and pyelonephritis, suggesting that 
combining antigenic motifs found in these proteins may be an effective multivalent vaccine 
for UTI (26). 
Other vaccine targets 
Vaccines consisting of bacterial components or whole cells have also been assessed. 
Transurethral immunization of mice with a live-attenuated UPEC strain lacking the ability 
to persist in the urinary tract engendered heterologous protection (145) a potential platform 
for further development. SolcoUrovac, a vaginal suppository containing 10 heat-killed 
uropathogenic strains, has been tested in mice , in nonhuman primates , and in clinical trials 
(26). While safe, SolcoUrovac vaccination did not result in appreciable increases in local 
specific antibody, nor did it afford protection without periodic readministration (146). 
Vaccine strategies to combat UTIs 
Since B and T cells, which mediate adaptive immunity are critically dependent on signals 
derived from the innate immune system, modulators that boost innate immune responses 
may be of value in boosting adaptive immune responses (147-150). Thus, 
immunomodulators used to boost innate immune responses in the urinary tract may be also 
employed to boost adaptive immune responses. One of the reasons for administering 
vaccine antigens against UTIs in the genitourinary tract, as in the case of the vaginal 
mucosal vaccine mentioned above, is to evoke secretory IgA (sIgA) antibodies in the 
mucosal surfaces of the urinary tract. Whereas subcutaneous, intramuscular, or intravenous 
immunization evokes strong systemic IgG responses to the vaccine antigens, they fail to 
evoke IgA antibodies in the mucosal surfaces of the urinary tract where infections are 
initiated and where antibodies are most needed (111).  
However, administering vaccines directly to the urinary tract is neither easy nor practical. A 
much more accessible mucosal site for the delivery of vaccines is the nasal passages. 
Delivery of proteus antigens into the nasal passages of mice have been shown to evoke high 
levels of sIgA in the urine and this was accompanied by impressive protection against 
Proteus mirabilis induced UTI (151). Immunization at nasal sites has been shown to be highly 
effective in evoking antigen specific serum IgG as well as sIgA responses in various mucosal 
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sites presumably due to activation of the nasal associated lymphoid tissue (NALT) found in 
the nasal passage. Since the NALT is a potent immunologically inductive and sampling site, 
it can respond vigorously to vaccine antigens and if TLR ligands or other adjuvants are 
present, this response may be even more magnified (152). Taken together, an alternate or 
complementary approach for the management of UTIs in the future could be targeted 
administration of modulators of the TLR signalling pathway to boost both innate and 
adaptive responses in the urinary tract. 
Cumulatively, all the indications suggest that the urinary tract is able to mount an 
appreciable and protective adaptive immune response and that this property can be 
harnessed for vaccination purposes. An important and as yet unanswered question is the 
duration of protection in the urinary tract following infection or vaccination. Since up to 
25% of women with UTIs that have no underlying immune competency issues have 
recurrences (153) it is conceivable that the immunity generated in the urinary tract could be 
relatively short lived and therefore frequent vaccinations may be required. 
6. Conclusion 
The over use of broad spectrum antibiotics has led to the emergence of antibiotic resistant 
bacteria many of which have been implicated in UTIs. As a consequence, management of 
these infections constitutes a serious and growing medical challenge. Modulating or co-
opting the powerful innate and adaptive immune systems of the urinary tract could 
potentially have important therapeutic and prophylactic implications for the treatment of 
UTIs, particularly where conventional approaches are ineffective.  
There is considerable work to be done to better understand the mechanisms of protective 
immunity against UPEC in the bladder. Specifically, available knockout mouse strains could 
be used to systematically evaluate the role of various receptors, signaling molecules, 
cytokines and chemokines, and cell types in controlling UPEC-mediated UTI and eliciting 
potent adaptive and memory immune responses. Ideally, the field can acquire insights on 
UTI immunity at a level suitable to rationally develop a much-needed vaccine that elicits 
sterilizing immunity against UPEC in the human urinary tract. 
Unlike antibiotic treatment, immunomodulation will not be broadly applicable. Instead, it 
will have to be tailored to each patient and must take into consideration, among other 
factors, the virulence and antibiotic resistance profile of the infecting bacteria as well as the 
age, immune competence and genetic make-up of the patient. For example, employing TLR4 
ligands to boost immunity in patients with defective TLR4 genes will not be productive but 
the use of activators of downstream components of the pathway could be useful. Thus, for 
these proposed emerging strategies to be completely effective, comprehensive information 
regarding relevant traits of the pathogen and the host will become necessary. 
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